Literature DB >> 22284787

Rotavirus diversity and evolution in the post-vaccine world.

John T Patton1.   

Abstract

Rotaviruses (RVs) are a large genetically diverse population of segmented double-stranded (ds) RNA viruses that are important causes of gastroenteritis in many animal species. The human RVs are responsible for the deaths of nearly 450,000 infants and young children each year, most occurring in developing countries. Recent large-scale sequencing efforts have revealed that the genomes of human RVs typically consist of phylogenetically linked constellations of eleven dsRNA segments. The presence of such preferred constellations indicate that the human RV genes have co-evolved to produce protein sets that work optimally together to support virus replication. Two of the viral genes encode virion outer capsid proteins (VP7 and VP4) whose antigenic properties define the G/P type of the virus. From year-to-year and place-to-place, the G/P type of human RVs associated with disease can fluctuate dramatically, phenomena that can be associated with the presence and behavior of genetically distinct RV clades. The recent introduction of two live attenuated RV vaccines [RotaTeq (TM) and Rotarix (TM)] into the childhood vaccination programs of various countries has been highly effective in reducing the incidence of RV diarrheal disease. Whether the widespread use of these vaccines will introduce selective pressures on human RVs, triggering genetic and antigenic changes that undermine the effectiveness of vaccinations programs, is uncertain and will require continued surveillance of human RVs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22284787      PMCID: PMC3738915     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  92 in total

1.  VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation.

Authors:  Jelle Matthijnssens; Peter H Otto; Max Ciarlet; Ulrich Desselberger; Marc Van Ranst; Reimar Johne
Journal:  Arch Virol       Date:  2012-03-20       Impact factor: 2.574

2.  Trials of oral bovine and rhesus rotavirus vaccines in Finland: a historical account and present status.

Authors:  T Vesikari
Journal:  Arch Virol Suppl       Date:  1996

Review 3.  2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; A Duncan Steele; Jazmin Duque; Umesh D Parashar
Journal:  Lancet Infect Dis       Date:  2011-10-24       Impact factor: 25.071

4.  Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq.

Authors:  Mark Zeller; John T Patton; Elisabeth Heylen; Sarah De Coster; Max Ciarlet; Marc Van Ranst; Jelle Matthijnssens
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

5.  Intra-genotypic diversity of archival G4P[8] human rotaviruses from Washington, DC.

Authors:  Sarah M McDonald; Kristin Davis; John K McAllen; David J Spiro; John T Patton
Journal:  Infect Genet Evol       Date:  2011-06-25       Impact factor: 3.342

6.  Global seasonality of rotavirus infections.

Authors:  S M Cook; R I Glass; C W LeBaron; M S Ho
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

7.  The genome segments of a group D rotavirus possess group A-like conserved termini but encode group-specific proteins.

Authors:  Eva Trojnar; Peter Otto; Bernhard Roth; Jochen Reetz; Reimar Johne
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

8.  Group A human rotavirus genomics: evidence that gene constellations are influenced by viral protein interactions.

Authors:  Erica M Heiman; Sarah M McDonald; Mario Barro; Zenobia F Taraporewala; Tamara Bar-Magen; John T Patton
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

9.  Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program.

Authors:  Daniel C Payne; Peter G Szilagyi; Mary Allen Staat; Kathryn M Edwards; Jon R Gentsch; Geoffrey A Weinberg; Caroline B Hall; Aaron T Curns; Haley Clayton; Marie R Griffin; Gerry Fairbrother; Umesh D Parashar
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

10.  Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil.

Authors:  Jailson B Correia; Manish M Patel; Osamu Nakagomi; Fernanda M U Montenegro; Eliane M Germano; Nancy B Correia; Luis E Cuevas; Umesh D Parashar; Nigel A Cunliffe; Toyoko Nakagomi
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  49 in total

Review 1.  Epidemiological and clinical studies of rotavirus-induced diarrhea in China from 1994-2013.

Authors:  Xiao Nan; Wu Jinyuan; Zhou Yan; Sun Maosheng; Li Hongjun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain.

Authors:  Olga Redondo; Rosa Cano; Lorena Simón
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Genotypic Distribution of Rotavirus in Phnom Penh, Cambodia: An Association of G9 with More Severe Diseases.

Authors:  Sasikorn Silapong; Pimmada Sakpaisal; Ladaporn Bodhidatta; Paphavee Lertsethtakarn; Orntipa Sethabutr; Ket Vansith; Chhour Y Meng; Brett E Swierczewski; Carl J Mason
Journal:  Am J Trop Med Hyg       Date:  2017-02-06       Impact factor: 2.345

4.  Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United States.

Authors:  Kristen M Ogden; Yi Tan; Asmik Akopov; Laura S Stewart; Rendie McHenry; Christopher J Fonnesbeck; Bhinnata Piya; Maximilian H Carter; Nadia B Fedorova; Rebecca A Halpin; Meghan H Shilts; Kathryn M Edwards; Daniel C Payne; Mathew D Esona; Slavica Mijatovic-Rustempasic; James D Chappell; John T Patton; Natasha B Halasa; Suman R Das
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

5.  Molecular-Genetic Characterization of Human Rotavirus A Strains Circulating in Moscow, Russia (2009-2014).

Authors:  Victoria Kiseleva; Evgeny Faizuloev; Elena Meskina; Anna Marova; Alexey Oksanich; Tatiana Samartseva; Georgy Bakhtoyarov; Natalia Bochkareva; Nikolay Filatov; Andrey Linok; Yulia Ammour; Vitaly Zverev
Journal:  Virol Sin       Date:  2018-07-30       Impact factor: 4.327

6.  Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco.

Authors:  Mohammed Benhafid; Nezha Elomari; Meryem Azzouzi Idrissi; Ahmed Rguig; Jon R Gentsch; Umesh Parashar; Rajae Elaouad
Journal:  J Med Virol       Date:  2015-03-05       Impact factor: 2.327

Review 7.  Structural features of glycan recognition among viral pathogens.

Authors:  Sreejesh Shanker; Liya Hu; Sasirekha Ramani; Robert L Atmar; Mary K Estes; B V Venkataram Prasad
Journal:  Curr Opin Struct Biol       Date:  2017-06-04       Impact factor: 6.809

Review 8.  Viral phosphodiesterases that antagonize double-stranded RNA signaling to RNase L by degrading 2-5A.

Authors:  Robert H Silverman; Susan R Weiss
Journal:  J Interferon Cytokine Res       Date:  2014-06       Impact factor: 2.607

9.  Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: footprints of a globally transitioning genotype.

Authors:  Allison F Dennis; Sarah M McDonald; Daniel C Payne; Slavica Mijatovic-Rustempasic; Mathew D Esona; Kathryn M Edwards; James D Chappell; John T Patton
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

10.  Surveillance and molecular characterization of group A rotaviruses in Goroka, Papua New Guinea.

Authors:  Paul Francis Horwood; Dagwin Luang-Suarkia; Sauli Bebes; Karen Boniface; Siddhartha Sankar Datta; Peter Max Siba; Carl Dunn Kirkwood
Journal:  Am J Trop Med Hyg       Date:  2012-11-05       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.